Clinical Trials
12 trialsNCT03498521 2025-11-19
CUPISCO
Hoffmann-La Roche
Phase 2 Completed
NCT00848718 2019-11-12
MK-2206-003
Merck Sharp & Dohme LLC
Phase 1 Completed
NCT01376310 2019-02-19
GSK1120212 Rollover Study
Novartis
Phase 2 Terminated
NCT01284335 2019-01-10
A Safety Study in Participants With Advanced Solid Tumors
Eli Lilly and Company
Phase 1 Terminated
NCT00954512 2018-08-24
Study of Robatumumab (SCH 717454, MK-7454) in Combination With Different Treatment Regimens in Participants With Advanced Solid Tumors (P04722, MK-7454-004)
Merck Sharp & Dohme LLC
Phase 1/2 Terminated
NCT00369512 2017-05-30
RAD0503
University of Alabama at Birmingham
Phase 2 Completed
NCT00737243 2016-08-17
Treatment Based on Molecular Profiling Diagnosis Carcinoma of Unknown Primary Site
SCRI Development Innovations, LLC
Phase 2 Completed
NCT00585377 2015-09-24
Bevacizumab (Avastin®) + Erlotinib as First-line Therapy for Stage IIIB/IV or Recurrent, Non-squamous Cell Lung Cancer
University of Utah
Phase 2 Completed
NCT01009203 2015-08-10
Temsirolimus (Torisel®) and Erlotinib (Tarceva®) in Platinum-Refractory/Ineligible, Advanced, Squamous Cell Carcinoma
New Mexico Cancer Research Alliance
Phase 2 Terminated
NCT00476476 2015-05-07
Erlotinib in Women With Squamous Cell Carcinoma of the Vulvar
Dana-Farber Cancer Institute
Phase 2 Completed
NCT00360360 2013-12-04
Paclitaxel/Carboplatin Plus Bevacizumab/Erlotinib in the First Line Treatment of Carcinoma of Unknown Primary Site
SCRI Development Innovations, LLC
Phase 2 Completed
NCT00611468 2011-08-22
Phase I, Dosage-finding and PK Study of IV Topotecan and Erlotinib With Refractory Solid Tumors
Accelerated Community Oncology Research Network
Phase 1 Completed